InSilico Medicine Cayman TopCo (abbreviated as INSILICO) modestly expanded its share base during August 2026 while confirming full compliance with Hong Kong Stock Exchange (HKEX) public-float requirements.

Share Capital • Authorised share capital remained unchanged at 1.27 billion ordinary shares with a par value of USD 0.0000005 each, equivalent to USD 635 in aggregate.

Issued Shares • Month-end issued share count (excluding treasury shares) rose to 582.68 million, up by 247,264 shares, or 0.04 % versus July’s close. • Treasury shares stood at zero; therefore, total issued shares equal outstanding shares.

Drivers of Issuance • 200,000 new shares were created through the exercise of options granted under multiple Pre-IPO equity incentive plans, generating proceeds of HKD 0.20 million. • A further 47,264 shares were issued upon vesting of restricted share units (RSUs) from Pre-IPO schemes. • During the month, 122,340 options lapsed, leaving 20.17 million options outstanding under Pre-IPO plans and capacity for an additional 17.12 million shares to be issued. • The Post-IPO Share Option Scheme, approved on 15 December 2025, had no options outstanding at month-end but can issue up to 24.59 million shares.

Public Float • INSILICO affirmed that at 31 August 2026 it satisfied HKEX’s minimum public-float threshold of 15 % of issued shares.

No activity was recorded in warrants, convertibles, treasury share movements, or Hong Kong Depositary Receipts during the period.

The monthly return, filed on 4 September 2026 and signed by Chairman and CEO Aleksandr Zavoronkov, confirms all issuances complied with relevant regulatory, listing-rule and corporate-governance requirements.